Cargando…
Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients
Amyotrophic lateral sclerosis (ALS) is an adult-onset disease characterized by the selective degeneration of motor neurons in the brain and spinal cord progressively leading to paralysis and death. Current diagnosis of ALS is based on clinical assessment of related symptoms. The clinical manifestati...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359444/ https://www.ncbi.nlm.nih.gov/pubmed/25637145 http://dx.doi.org/10.1186/s40478-014-0181-z |
_version_ | 1782361408226197504 |
---|---|
author | Paré, Bastien Touzel-Deschênes, Lydia Lamontagne, Rémy Lamarre, Marie-Soleil Scott, François-Dominique Khuong, Hélène T Dion, Patrick A Bouchard, Jean-Pierre Gould, Peter Rouleau, Guy A Dupré, Nicolas Berthod, François Gros-Louis, François |
author_facet | Paré, Bastien Touzel-Deschênes, Lydia Lamontagne, Rémy Lamarre, Marie-Soleil Scott, François-Dominique Khuong, Hélène T Dion, Patrick A Bouchard, Jean-Pierre Gould, Peter Rouleau, Guy A Dupré, Nicolas Berthod, François Gros-Louis, François |
author_sort | Paré, Bastien |
collection | PubMed |
description | Amyotrophic lateral sclerosis (ALS) is an adult-onset disease characterized by the selective degeneration of motor neurons in the brain and spinal cord progressively leading to paralysis and death. Current diagnosis of ALS is based on clinical assessment of related symptoms. The clinical manifestations observed in ALS appear relatively late in the disease course after degeneration of a significant number of motor neurons. As a result, the identification and development of disease-modifying therapies is difficult. Therefore, novel strategies for early diagnosis of neurodegeneration, to monitor disease progression and to assess response to existing and future treatments are urgently needed. Factually, many neurological disorders, including ALS, are accompanied by skin changes that often precede the onset of neurological symptoms. Aiming to generate an innovative human-based model to facilitate the identification of predictive biomarkers associated with the disease, we developed a unique ALS tissue-engineered skin model (ALS-TES) derived from patient’s own cells. The ALS-TES presents a number of striking features including altered epidermal differentiation, abnormal dermo-epidermal junction, delamination, keratinocyte infiltration, collagen disorganization and cytoplasmic TDP-43 inclusions. Remarkably, these abnormal skin defects, uniquely seen in the ALS-derived skins, were detected in pre-symtomatic C9orf72-linked ALS patients carrying the GGGGCC DNA repeat expansion. Consequently, our ALS skin model could represent a renewable source of human tissue, quickly and easily accessible to better understand the physiopathological mechanisms underlying this disease, to facilitate the identification of disease-specific biomarkers, and to develop innovative tools for early diagnosis and disease monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40478-014-0181-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4359444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43594442015-03-15 Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients Paré, Bastien Touzel-Deschênes, Lydia Lamontagne, Rémy Lamarre, Marie-Soleil Scott, François-Dominique Khuong, Hélène T Dion, Patrick A Bouchard, Jean-Pierre Gould, Peter Rouleau, Guy A Dupré, Nicolas Berthod, François Gros-Louis, François Acta Neuropathol Commun Research Amyotrophic lateral sclerosis (ALS) is an adult-onset disease characterized by the selective degeneration of motor neurons in the brain and spinal cord progressively leading to paralysis and death. Current diagnosis of ALS is based on clinical assessment of related symptoms. The clinical manifestations observed in ALS appear relatively late in the disease course after degeneration of a significant number of motor neurons. As a result, the identification and development of disease-modifying therapies is difficult. Therefore, novel strategies for early diagnosis of neurodegeneration, to monitor disease progression and to assess response to existing and future treatments are urgently needed. Factually, many neurological disorders, including ALS, are accompanied by skin changes that often precede the onset of neurological symptoms. Aiming to generate an innovative human-based model to facilitate the identification of predictive biomarkers associated with the disease, we developed a unique ALS tissue-engineered skin model (ALS-TES) derived from patient’s own cells. The ALS-TES presents a number of striking features including altered epidermal differentiation, abnormal dermo-epidermal junction, delamination, keratinocyte infiltration, collagen disorganization and cytoplasmic TDP-43 inclusions. Remarkably, these abnormal skin defects, uniquely seen in the ALS-derived skins, were detected in pre-symtomatic C9orf72-linked ALS patients carrying the GGGGCC DNA repeat expansion. Consequently, our ALS skin model could represent a renewable source of human tissue, quickly and easily accessible to better understand the physiopathological mechanisms underlying this disease, to facilitate the identification of disease-specific biomarkers, and to develop innovative tools for early diagnosis and disease monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40478-014-0181-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-01-31 /pmc/articles/PMC4359444/ /pubmed/25637145 http://dx.doi.org/10.1186/s40478-014-0181-z Text en © Paré et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Paré, Bastien Touzel-Deschênes, Lydia Lamontagne, Rémy Lamarre, Marie-Soleil Scott, François-Dominique Khuong, Hélène T Dion, Patrick A Bouchard, Jean-Pierre Gould, Peter Rouleau, Guy A Dupré, Nicolas Berthod, François Gros-Louis, François Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients |
title | Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients |
title_full | Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients |
title_fullStr | Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients |
title_full_unstemmed | Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients |
title_short | Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients |
title_sort | early detection of structural abnormalities and cytoplasmic accumulation of tdp-43 in tissue-engineered skins derived from als patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359444/ https://www.ncbi.nlm.nih.gov/pubmed/25637145 http://dx.doi.org/10.1186/s40478-014-0181-z |
work_keys_str_mv | AT parebastien earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT touzeldescheneslydia earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT lamontagneremy earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT lamarremariesoleil earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT scottfrancoisdominique earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT khuonghelenet earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT dionpatricka earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT bouchardjeanpierre earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT gouldpeter earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT rouleauguya earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT duprenicolas earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT berthodfrancois earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients AT groslouisfrancois earlydetectionofstructuralabnormalitiesandcytoplasmicaccumulationoftdp43intissueengineeredskinsderivedfromalspatients |